Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€8.18
Change (%) Stock is Down 0.2 (2.39%)
Volume42,428
Data as of 09/25/18 12:24 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
20-Sep-2018ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer. The TR... 
 Printer Friendly Version
13-Sep-2018ERYTECH to Attend Upcoming Investor Conferences
LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018: Conference Details: Morgan Stanley Global Healthcare Conference Attendee: Gil Beyen, Chief Executive Offi... 
 Printer Friendly Version
10-Sep-2018ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 11th at 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pancreatic cancer initiated and open for patient enrollment Phase 2 trial in triple-negative breast cancer on track for start of patient enrollment in Q4 Cash position of €165 million ($193 million) as of June 30, 2018 LYON , France and CAMBRIDGE, Mass., Sept. 10, 2018 (... 
 Printer Friendly Version
06-Sep-2018ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
(GLOBE NEWSWIRE via COMTEX) --LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. The call is accessible via the below te... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/13/18 2:30 p.m. CET
Erytech Pharma Third Quarter 2018 Conference Call and Webcast
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 

ERYTECH Pharma complies with GDPR regulations. For more information about your data, please click here.

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources